DiaMedica's Net Loss Widens on Soaring R&D Costs

TL;DR

**DMAC is burning cash at an alarming rate on R&D, and while PE data looks promising, the AIS trial is a mess, making this a risky bet.**

AI Summary

DiaMedica Therapeutics Inc. (DMAC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $24.026 million, up from $16.544 million in the prior year, representing a 45.2% increase. This was driven by a substantial rise in research and development (R&D) expenses, which climbed to $17.915 million from $12.587 million, a 42.3% increase, and general and administrative (G&A) expenses, which rose to $7.269 million from $5.675 million, a 28.1% increase. The company's cash and cash equivalents increased slightly to $3.326 million from $3.025 million at December 31, 2024, while marketable securities grew to $51.992 million from $41.122 million. Strategic outlook includes advancing its lead product candidate, DM199, for preeclampsia (PE) and acute ischemic stroke (AIS), with interim Phase 2 PE study results showing DM199 is safe, well-tolerated, and reduces blood pressure. However, the ReMEDy2 trial for AIS faces challenges with slower site activations and enrollment due to hospital staffing shortages and competition, prompting the company to expand its internal clinical team and globally expand the trial.

Why It Matters

DiaMedica's escalating R&D expenses, up 42.3% to $17.915 million, are critical for investors as they reflect the intense capital requirements of clinical-stage biopharmaceutical development. While the positive interim Phase 2 PE trial results for DM199 offer a glimmer of hope for future revenue streams, the significant challenges in the ReMEDy2 AIS trial, including slower enrollment and competition, could delay market entry and impact the company's competitive positioning against other stroke treatments. Employees and customers are directly affected by the success or failure of these trials, as it determines the company's long-term viability and the availability of potential new therapies for serious conditions like preeclampsia and acute ischemic stroke. The broader market watches these developments for indicators of innovation and investment trends in the biopharma sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $24.026 million for the nine months ended September 30, 2025, a 45.2% increase from the prior year, indicating significant cash burn. Furthermore, the ReMEDy2 clinical trial for AIS is experiencing 'slower than expected site activations and enrollment' due to 'hospital and medical facility staffing shortages' and 'competition for research staff and trial subjects,' posing substantial operational and financial risks to its primary product candidate.

Analyst Insight

Investors should exercise extreme caution and consider the high burn rate and clinical trial delays before investing. Monitor the progress of the ReMEDy2 trial closely for signs of improved enrollment and the initiation of Part 1b of the PE study, as these are critical milestones for future valuation.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$57.047M

total Debt

N/A

net Income

-$24.026M

eps

-$0.53

gross Margin

N/A

cash Position

$3.326M

revenue Growth

N/A

Key Numbers

• $24.026M — Net Loss (Increased 45.2% for the nine months ended September 30, 2025, from $16.544 million in 2024.)
• $17.915M — Research and Development Expenses (Increased 42.3% for the nine months ended September 30, 2025, from $12.587 million in 2024.)
• $7.269M — General and Administrative Expenses (Increased 28.1% for the nine months ended September 30, 2025, from $5.675 million in 2024.)
• $51.992M — Marketable Securities (Increased from $41.122 million at December 31, 2024, indicating capital raised.)
• 52,077,439 — Common Shares Outstanding (As of November 10, 2025, reflecting recent share issuances.)
• $31.527M — Proceeds from Sale of Common Shares (Net of offering costs, for the nine months ended September 30, 2025.)

Key Players & Entities

• DiaMedica Therapeutics Inc. (company) — registrant
• DM199 (company) — lead product candidate
• Tygerberg Hospital (company) — site of Phase 2 PE study
• U.S. Food and Drug Administration (regulator) — regulatory body
• The Nasdaq Stock Market LLC (company) — exchange where DMAC is traded
• DiaMedica USA Inc. (company) — wholly owned subsidiary
• DiaMedica Australia Pty Ltd. (company) — wholly owned subsidiary

FAQ

Risk Factors

• Clinical Trial Delays and Enrollment Challenges [high — operational]: The ReMEDy2 trial for acute ischemic stroke (AIS) is experiencing slower site activations and enrollment due to hospital staffing shortages and competition. This has prompted the company to expand its internal clinical team and globally expand the trial, indicating potential cost overruns and extended timelines.
• Regulatory Approval Uncertainty for DM199 [high — regulatory]: The company's plans to obtain regulatory approval for DM199 for preeclampsia (PE) and acute ischemic stroke (AIS) are subject to successful clinical testing and regulatory review. Any delays or failures in clinical trials could significantly impact the company's ability to bring its lead product candidate to market.
• Increasing Net Loss and Burn Rate [high — financial]: The net loss for the nine months ended September 30, 2025, increased by 45.2% to $24.026 million from $16.544 million in the prior year. This is driven by a 42.3% increase in R&D expenses and a 28.1% increase in G&A expenses, suggesting a rising burn rate that will require significant future funding.
• Dependence on Marketable Securities for Liquidity [medium — financial]: While cash and cash equivalents saw a slight increase to $3.326 million, the company's liquidity is heavily reliant on its marketable securities, which grew to $51.992 million. A significant downturn in the market could impact the value of these securities and the company's financial flexibility.
• Reliance on a Single Product Candidate [high — operational]: The company's future success is largely dependent on the development and commercialization of DM199. Any setbacks with this single product candidate could have a catastrophic impact on the company's prospects.

Industry Context

DiaMedica operates in the biopharmaceutical industry, focusing on developing novel therapeutics for cardiovascular and neurological diseases. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like DiaMedica face intense competition from larger pharmaceutical firms and other biotech startups, necessitating strong clinical trial execution and effective capital management.

Regulatory Implications

The company's progress is heavily dependent on obtaining regulatory approval from bodies like the FDA for its lead candidate, DM199. Delays in clinical trials or failure to meet efficacy endpoints could lead to significant setbacks. The company must navigate complex regulatory pathways for both preeclampsia and acute ischemic stroke indications.

What Investors Should Do

1. Monitor clinical trial progress and enrollment rates for the ReMEDy2 trial.
2. Evaluate the company's cash burn rate and future financing needs.
3. Assess the interim Phase 2 PE study results for DM199.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a significant increase in net loss to $24.026 million, driven by higher R&D and G&A expenses.
• 2025-12-31: As of December 31, 2024 — Company had $3.025 million in cash and cash equivalents and $41.122 million in marketable securities.
• 2025-11-10: As of November 10, 2025 — Common shares outstanding were 52,077,439, reflecting recent share issuances.

Glossary

DM199

DiaMedica's lead product candidate. (It is the primary focus of the company's development efforts for treating preeclampsia and acute ischemic stroke.)

Preeclampsia (PE)

A serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys. (One of the key indications for which DM199 is being developed.)

Acute Ischemic Stroke (AIS)

A stroke caused by a blocked artery that supplies blood to the brain. (The other key indication for which DM199 is being developed.)

Investigational New Drug (IND) application

A submission to the FDA that allows for the clinical investigation of a new drug. (Required before DM199 can be further tested in clinical studies for its target indications.)

Marketable securities

Investments that are readily convertible to cash, such as stocks and bonds. (A significant component of the company's assets, providing liquidity and funding for operations.)

Accumulated deficit

The cumulative net losses of a company since its inception. (Indicates the company has not yet achieved profitability, with a deficit of $164.028 million as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year, DiaMedica Therapeutics Inc. has experienced a substantial increase in its net loss, up 45.2% to $24.026 million for the nine months ended September 30, 2025. This widening loss is primarily attributed to a 42.3% surge in R&D expenses and a 28.1% rise in G&A costs. While marketable securities have grown significantly from $41.122 million to $51.992 million, indicating successful capital raising, the overall financial trend points to increased operational spending and a higher burn rate.

Filing Documents

• dmtp20250930_10q.htm (10-Q) — 935KB
• ex_886862.htm (EX-10.3) — 199KB
• ex_884117.htm (EX-10.5) — 95KB
• ex_884116.htm (EX-31.1) — 19KB
• ex_884115.htm (EX-31.2) — 19KB
• ex_884114.htm (EX-32.1) — 4KB
• ex_884113.htm (EX-32.2) — 5KB
• img2.jpg (GRAPHIC) — 97KB
• logo1.jpg (GRAPHIC) — 21KB
• 0001437749-25-034469.txt ( ) — 5360KB
• dmac-20250930.xsd (EX-101.SCH) — 43KB
• dmac-20250930_def.xml (EX-101.DEF) — 291KB
• dmac-20250930_lab.xml (EX-101.LAB) — 239KB
• dmac-20250930_pre.xml (EX-101.PRE) — 320KB
• dmac-20250930_cal.xml (EX-101.CAL) — 35KB
• dmtp20250930_10q_htm.xml (XML) — 699KB

Financial Statements

Financial Statements 2 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 SIGNATURE PAGE 24 This quarterly report on Form 10-Q contains certain forward-looking statements that are within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see " Cautionary Note Regarding Forward-Looking Statements. " As used in this report, references to " DiaMedica, " the " Company, " " we, " " our " or " us, " unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica ' s condensed consolidated financial statements. References in this report to " common shares " mean our voting common shares, no par value per share. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the and symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies ' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS DiaMedica Therapeutics Inc. Condensed Consolidated Balance Sheets (In thousands, except share amounts) September 30, 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 3,326 $ 3,025 Marketable securities 51,992 41,122 Prepaid expenses and other assets 445 227 Amounts receivable 260 236 Deposits 200 — Total current assets 56,223 44,610 Non-current assets: Deferred offering costs 456 — Operating lease right-of-use asset, net 218 279 Property and equipment, net 150 148 Deposits — 1,308 Total non-current assets 824 1,735 Total assets $ 57,047 $ 46,345 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,920 $ 940 Accrued liabilities 3,239 4,347 Operating lease obligation 99 90 Finance lease obligation 10 13 Total current liabilities 5,268 5,390 Non-current liabilities: Operating lease obligation 150 225 Finance lease obligation 7 12 Total non-current liabilities 157 237 Shareholders' equity: Common shares, no par value; unlimited authorized; 52,077,439 and 42,818,660 shares issued and outstanding, as of September 30, 2025 and December 31, 2024, respectively — — Paid-in capital 215,600 180,697 Accumulated other comprehensive income 50 23 Accumulated deficit ( 164,028 ) ( 140,002 ) Total shareholders' equity 51,622 40,718 Total liabilities and shareholders' equity $ 57,047 $ 46,345 See accompanying notes to the condensed consolidated financial statements. 2 DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 6,437 $ 4,983 $ 17,915 $ 12,587 General and administrativ

View Full Filing

View this 10-Q filing on SEC EDGAR